Sort   by:  
 Page size 
UnknownPatient experience and attitudes toward addressing the cost of breast cancer care.
Not available
S-EPMC4221364 | biostudies-literature
TranscriptomicsPrototypes for 4x44K PAM50 Subtyping
PAM50 intrinsic subtype classification (Parker JS, Mullins M, Cheang MCU, et al: Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol 27:1160-1167, 2009) was used for the Z1031 patient cohort. However, to account for potential technical biases such as differences in ...
ORGANISM(S): Homo sapiens 
2011-05-10 | E-GEOD-26082 | biostudies-arrayexpress
UnknownThe effect of treatment on patient-reported distress after breast cancer diagnosis.
Not available
S-EPMC6690752 | biostudies-literature
UnknownImproved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Not available
S-EPMC3683862 | biostudies-literature
UnknownCirculating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients.
Not available
S-EPMC8196036 | biostudies-literature
TranscriptomicsTBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple Negative Breast Cancer
Abstract Background. Epidermal growth factor receptor (EGFR) is a targetable molecule in basal-like breast cancer, which comprises most “triple negative” breast cancer (TNBC), the only breast cancer subtype without established targeted therapy. Methods. In this randomized phase II trial, metastatic ...
ORGANISM(S): Homo sapiens 
2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress
GenomicsEstrogen Receptor Positive Breast Cancer: Aromatase Inhibitor Response Study

Highly variable outcomes are observed in patients with estrogen receptor positive (ER+) breast cancer who undergo preoperative estrogen deprivation therapy with aromatase inhibitors (AI). In this study, 46 tumor and normal genomes and 31 exomes of participants selected from two clinical trials of...

phs000472.v1.p1 | EGA
UnknownRandomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Not available
S-EPMC3107749 | biostudies-literature
TranscriptomicsNovel linkages between DCE-MRI and genomic profiling in locally advanced and inflammatory breast cancer
Gene expression signatures have the capacity to identify clinically significant features of breast cancer and can predict which individual patients are likely to be resistant to neoadjuvant therapy, thus providing the opportunity to guide treatment decisions. Data used in publication: Clin Cancer Re...
ORGANISM(S): Homo sapiens 
2014-03-31 | E-GEOD-52322 | biostudies-arrayexpress
TranscriptomicsBRC77 Agilent Gene Expression Arrays
Agilent 44K whole genome studies were used to correlate gene expression values with mutations found in massively parallel sequencing experiments. 77 patients were profiled using Agilent's two-color microarray platform. Tumor(cy5) was co-hybridized to a reference(cy3).
ORGANISM(S): Homo sapiens 
2012-06-20 | E-GEOD-29442 | biostudies-arrayexpress
Sort   by:  
 Page size